📊 FDMT Key Takeaways
Is 4D Molecular Therapeutics, Inc. (FDMT) a Good Investment?
4D Molecular Therapeutics is burning $68.1M in operating cash annually while generating only $3.0M in revenue, yielding approximately 11 months of cash runway at current burn rates. The company exhibits zero revenue growth, negative operating margins exceeding -2400%, and lacks evidence of imminent product commercialization or profitability, creating an unsustainable financial position that threatens shareholder value destruction.
4D Molecular Therapeutics shows very weak operating fundamentals, with deeply negative operating and net margins, substantial annual cash burn, and no evidence of improving revenue momentum in the latest period. The balance sheet is currently supported by high liquidity, no long-term debt, and a large equity base, but the business remains dependent on external funding or future clinical/commercial execution to offset persistent losses.
4D Molecular Therapeutics, Inc. Key Strengths (FDMT)
- Strong balance sheet with $451.8M stockholders' equity and minimal debt (0.00x debt/equity)
- Substantial cash reserves of $72.5M providing near-term operational runway
- Excellent liquidity position with 9.34x current ratio, ensuring short-term payment capability
- Low capital intensity with only $536K capex, reducing dilutive financing needs
- Strong near-term liquidity with 9.39x current and quick ratios
- Debt-free capital structure with 0.00x debt-to-equity
- Large equity base relative to liabilities, providing balance sheet flexibility
FDMT Stock Risks: 4D Molecular Therapeutics, Inc. Investment Risks
- Catastrophic cash burn of $68.1M annually against $3.0M revenue base is fundamentally unsustainable
- Cash depletion timeline of approximately 1 year at current operating burn rate without revenue acceleration
- Complete stagnation with 0.0% revenue growth and no visible path to profitability or positive operating cash flow
- Operating margins of -2416% and net margins of -2256% indicate severe operational distress and loss of shareholder capital
- Pre-commercial biotech business model with unproven ability to generate material product revenue within runway window
- Severely negative profitability, including -187.2% operating margin and -164.4% net margin
- Sustained negative free cash flow of about $109.62M indicates ongoing cash consumption
- Flat revenue growth suggests weak current growth quality and limited operating leverage
Key Metrics to Watch
- Operating cash flow trend and quarterly burn rate reduction toward sustainability
- Revenue growth acceleration and product commercialization milestones
- Cash position depletion rate and runway extension through partnerships, financing, or profitability
- Operating expense management and path to operating breakeven
- Quarterly operating cash burn relative to cash and short-term liquidity
- Revenue durability and any improvement in operating loss trend
4D Molecular Therapeutics, Inc. (FDMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.34x current ratio provides a solid financial cushion.
FDMT Profit Margin, ROE & Profitability Analysis
FDMT vs Healthcare Sector: How 4D Molecular Therapeutics, Inc. Compares
How 4D Molecular Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is 4D Molecular Therapeutics, Inc. Stock Overvalued? FDMT Valuation Analysis 2026
Based on fundamental analysis, 4D Molecular Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
4D Molecular Therapeutics, Inc. Balance Sheet: FDMT Debt, Cash & Liquidity
FDMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: 4D Molecular Therapeutics, Inc.'s revenue has grown significantly by 372% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.98 indicates the company is currently unprofitable.
FDMT Revenue Growth, EPS Growth & YoY Performance
FDMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.0K | -$48.0M | $-0.86 |
| Q3 2025 | $3.0K | -$32.4M | $-0.79 |
| Q2 2025 | $5.0K | -$32.4M | $-0.63 |
| Q1 2025 | $14.0K | -$32.4M | $-0.66 |
| Q3 2024 | $3.0K | -$10.3M | $-0.24 |
| Q2 2024 | $5.0K | -$28.7M | $-0.63 |
| Q1 2024 | $28.0K | -$28.7M | $-0.66 |
| Q3 2023 | $500.0K | -$10.3M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
4D Molecular Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
FDMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for 4D Molecular Therapeutics, Inc. (CIK: 0001650648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FDMT
What is the AI rating for FDMT?
4D Molecular Therapeutics, Inc. (FDMT) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FDMT's key strengths?
Claude: Strong balance sheet with $451.8M stockholders' equity and minimal debt (0.00x debt/equity). Substantial cash reserves of $72.5M providing near-term operational runway. ChatGPT: Strong near-term liquidity with 9.39x current and quick ratios. Debt-free capital structure with 0.00x debt-to-equity.
What are the risks of investing in FDMT?
Claude: Catastrophic cash burn of $68.1M annually against $3.0M revenue base is fundamentally unsustainable. Cash depletion timeline of approximately 1 year at current operating burn rate without revenue acceleration. ChatGPT: Severely negative profitability, including -187.2% operating margin and -164.4% net margin. Sustained negative free cash flow of about $109.62M indicates ongoing cash consumption.
What is FDMT's revenue and growth?
4D Molecular Therapeutics, Inc. reported revenue of $3.0M.
Does FDMT pay dividends?
4D Molecular Therapeutics, Inc. does not currently pay dividends.
Where can I find FDMT SEC filings?
Official SEC filings for 4D Molecular Therapeutics, Inc. (CIK: 0001650648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FDMT's EPS?
4D Molecular Therapeutics, Inc. has a diluted EPS of $-1.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FDMT's fundamental grade?
Based on our AI fundamental analysis in June 2026, 4D Molecular Therapeutics, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FDMT stock overvalued or undervalued?
Valuation metrics for FDMT: ROE of -15.2% (sector avg: 15%), net margin of -2,256.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FDMT's AI grade for 2026?
Our dual AI analysis gives 4D Molecular Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FDMT's free cash flow?
4D Molecular Therapeutics, Inc.'s operating cash flow is $-68.1M, with capital expenditures of $536.0K. FCF margin is -2,253.4%.
How does FDMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,256.6% (avg: 12%), ROE -15.2% (avg: 15%), current ratio 9.34 (avg: 2).